Sorrento's R&D wa ni idojukọ lori imotuntun awakọ ni COVID-19, itọju alakan, iṣakoso irora ni kikun ati awọn aarun autoimmune

Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
Awọn eto COVID-19
COVISTIX™ (aisan ayẹwo) Dekun Antijeni igbeyewo 0%* Aṣẹ Lilo pajawiri (EUA) ni Mexico (COFEPRIS), Brazil (ANVISA), ati CE Ti samisi ni Yuroopu COVIMARK™ (aisan ayẹwo) Dekun Antijeni igbeyewo 0%* Ohun elo ti a fi silẹ ni AMẸRIKA ati Kanada fun Aṣẹ Lilo pajawiri (EUA) VIREX (aisan ayẹwo) Ni Ile Aisan 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS nitori COVID-19 ni Awọn alaisan ICU 82%* Idanwo pataki ni Ilu Brazil                           OVYDSO (Olgotrelvir) Alatako-ọlọjẹ (Oral pill) 40%* Omicron mRNA ajesara Ajesara 20%*
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
ajẹsara
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Ibo ori 20%* PD-L1 (Socazolimab)* SCLC 82%* * Ni Ajọṣepọ pẹlu Lee's Pharm ni Ilu China PD-L1 (STI-3031)** obo akàn 82%* ** Ni AMẸRIKA ati ni ajọṣepọ pẹlu ImmuneOncia ni Koria CD47 Awọn èèmọ to lagbara 40%* CD38 DAR-T Ọpọlọ Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal 40%* TROP2 ADC* Awọn èèmọ to lagbara 40%* Seprehvec™ oncolytic kokoro Awọn èèmọ to lagbara; Awọn èèmọ CNS 40%* BMA ADC Awọn èèmọ olomi 20%* Bevacizumab-ADNAB™ Ọgbẹ ti ipilẹṣẹ 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL), Melanoma 40%*
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
irora
ZTlido® 1.8% Neuralgia Postherpetic - PHN 99.8%* Gloperba® Itoju ti Gout (Oral) 99.8%* SEMEXA (SP-102) Lumbar Radicular/Irora Sciatica 82%* SP-103 (Eto Ipilẹ Lidocaine 5.4%) Irora Pada irora 60.2%* SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Abẹrẹ epidural Irora ti ko le fa ni Ilọsiwaju Akàn 60.3%* Orphan yiyan RTX (resiniferatoxin) Ona-intra-articular Iwontunwonsi si Irora Orunkun Okun 60.2%*
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
Ifijiṣẹ Oògùn Lymphatic
Sofusa® egboogi-TNF Aifọwọyi (RA) 40%* Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® egboogi-CTLA-4 Melanoma 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic

Awọn eto COVID-19
Awọn eto bọtini (Itọkasi)	alakoso
COVISTIX™ (aisan ayẹwo) FDA EUA COVIMARK™ (aisan ayẹwo) FDA EUA VIREX (aisan ayẹwo) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA ajesara Preclinical

ajẹsara
Awọn eto bọtini (Itọkasi)	alakoso
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Awọn èèmọ to lagbara) Ph I CD38 DAR-T (Ọpọ Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal) Ph I TROP2 ADC* (Awọn èèmọ to lagbara) Ph I Seprehvec™ oncolytic kokoro (Awọn èèmọ to lagbara; Awọn èèmọ CNS) PH I BMA ADC (Awọn èèmọ olomi) Preclinical Bevacizumab-ADNAB™ (Akàn Endometrial) Ph I Bevacizumab-ADNAB™ (Akàn Ovarian) Ph I Rituximab-ADNAB™ (Lymphomas B-cell) Ph I Sofusa® egboogi-PD-1 (T-Cell Lymphoma (CTCL), Melanoma) Ph I

irora
Awọn eto bọtini (Itọkasi)	alakoso
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval Gloperba® 1.8% Itoju ti Gout (Oral) FDA Approval SEMEXA (SP-102) Ph III SP-103 (Eto Ipilẹ Lidocaine 5.4%) Ph II SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Preclinical RTX (resiniferatoxin) Abẹrẹ epidural Ph II RTX (resiniferatoxin) Ona-intra-articular Ph II

Ifijiṣẹ Lymphatic
Awọn eto bọtini (Itọkasi)	Igbese II
Sofusa® egboogi-TNF (Autoimmune RA) Ph I Sofusa® egboogi-PD-1 (T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® egboogi-CTLA-4 (Melanoma) Ph I